Cargando…

Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management

Good glycaemic control continues to be the most effective therapeutic manoeuvre to reduce the risk of development and/or progression of microvascular disease, and therefore remains the cornerstone of diabetes management despite recent scepticism about tight glucose control strategies. The impact on...

Descripción completa

Detalles Bibliográficos
Autores principales: Prato, S Del, LaSalle, J, Matthaei, S, Bailey, C J
Formato: Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2010
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814090/
https://www.ncbi.nlm.nih.gov/pubmed/20456169
http://dx.doi.org/10.1111/j.1742-1241.2009.02227.x
_version_ 1782176973155467264
author Prato, S Del
LaSalle, J
Matthaei, S
Bailey, C J
author_facet Prato, S Del
LaSalle, J
Matthaei, S
Bailey, C J
author_sort Prato, S Del
collection PubMed
description Good glycaemic control continues to be the most effective therapeutic manoeuvre to reduce the risk of development and/or progression of microvascular disease, and therefore remains the cornerstone of diabetes management despite recent scepticism about tight glucose control strategies. The impact on macrovascular complications is still a matter of debate, and so glycaemic control strategies should be placed in the context of multifactorial intervention to address all cardiovascular risk factors. Approaches to achieve glycaemic targets should always ensure patient safety, and results from recent landmark outcome studies support the need for appropriate individualisation of glycaemic targets and of the means to achieve these targets, with the ultimate aim to optimise outcomes and minimise adverse events, such as hypoglycaemia and marked weight gain. The primary goal of the Global Partnership for Effective Diabetes Management is the provision of practical guidance to improve patient outcomes and, in this article, we aim to support healthcare professionals in appropriately tailoring type 2 diabetes treatment to the individual. Patient groups requiring special consideration are identified, including newly diagnosed individuals with type 2 diabetes but no complications, individuals with a history of inadequate glycaemic control, those with a history of cardiovascular disease, children and individuals at risk of hypoglycaemia. Practical guidance specific to each group is provided.
format Text
id pubmed-2814090
institution National Center for Biotechnology Information
language English
publishDate 2010
publisher Blackwell Publishing Ltd
record_format MEDLINE/PubMed
spelling pubmed-28140902010-02-12 Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management Prato, S Del LaSalle, J Matthaei, S Bailey, C J Int J Clin Pract Consensus Good glycaemic control continues to be the most effective therapeutic manoeuvre to reduce the risk of development and/or progression of microvascular disease, and therefore remains the cornerstone of diabetes management despite recent scepticism about tight glucose control strategies. The impact on macrovascular complications is still a matter of debate, and so glycaemic control strategies should be placed in the context of multifactorial intervention to address all cardiovascular risk factors. Approaches to achieve glycaemic targets should always ensure patient safety, and results from recent landmark outcome studies support the need for appropriate individualisation of glycaemic targets and of the means to achieve these targets, with the ultimate aim to optimise outcomes and minimise adverse events, such as hypoglycaemia and marked weight gain. The primary goal of the Global Partnership for Effective Diabetes Management is the provision of practical guidance to improve patient outcomes and, in this article, we aim to support healthcare professionals in appropriately tailoring type 2 diabetes treatment to the individual. Patient groups requiring special consideration are identified, including newly diagnosed individuals with type 2 diabetes but no complications, individuals with a history of inadequate glycaemic control, those with a history of cardiovascular disease, children and individuals at risk of hypoglycaemia. Practical guidance specific to each group is provided. Blackwell Publishing Ltd 2010-02 /pmc/articles/PMC2814090/ /pubmed/20456169 http://dx.doi.org/10.1111/j.1742-1241.2009.02227.x Text en © 2010 Blackwell Publishing Ltd http://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.
spellingShingle Consensus
Prato, S Del
LaSalle, J
Matthaei, S
Bailey, C J
Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management
title Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management
title_full Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management
title_fullStr Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management
title_full_unstemmed Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management
title_short Tailoring treatment to the individual in type 2 diabetes practical guidance from the Global Partnership for Effective Diabetes Management
title_sort tailoring treatment to the individual in type 2 diabetes practical guidance from the global partnership for effective diabetes management
topic Consensus
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2814090/
https://www.ncbi.nlm.nih.gov/pubmed/20456169
http://dx.doi.org/10.1111/j.1742-1241.2009.02227.x
work_keys_str_mv AT pratosdel tailoringtreatmenttotheindividualintype2diabetespracticalguidancefromtheglobalpartnershipforeffectivediabetesmanagement
AT lasallej tailoringtreatmenttotheindividualintype2diabetespracticalguidancefromtheglobalpartnershipforeffectivediabetesmanagement
AT matthaeis tailoringtreatmenttotheindividualintype2diabetespracticalguidancefromtheglobalpartnershipforeffectivediabetesmanagement
AT baileycj tailoringtreatmenttotheindividualintype2diabetespracticalguidancefromtheglobalpartnershipforeffectivediabetesmanagement